Showing 1511-1520 of 1614 results for "".
- Intelligent Retinal Imaging Systems (IRIS) Partners with Remidio Innovative Solutions to Provide Early Detection Systems for Diabetic Eye Diseasehttps://modernod.com/news/intelligent-retinal-imaging-systems-iris-partners-with-remidio-innovative-solutions-to-provide-early-detection-systems-for-diabetic-eye-disease/2476989/Intelligent Retinal Imaging Systems (IRIS) announced a partnership with Remidio Innovative Solutions to bring their smartphone based non-mydriatic fundus camera to the U.S. market. Coupling the IRIS software and services program with an affordable and high-quality handheld camera will allow more
- Product Specific J-Code for Omeros’ Omidria is Now in Effecthttps://modernod.com/news/product-specific-j-code-for-omeros-omidria-is-now-in-effect/2476927/Omeros announced that the product specific J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% is now effective. Omidria is Omeros’ commercial drug marketed for use during cataract surgery to prevent miosis and reduce postoperative pain. The new permanent J-code f
- Ocugen Announces Completion of its Merger with Histogenics to Create Ocular Gene Therapies and Biotherapeuticshttps://modernod.com/news/ocugen-announces-completion-of-its-merger-with-histogenics-to-create-ocular-gene-therapies-and-biotherapeutics/2476924/Ocugen announced the completion of its merger with Histogenics, and the change of the combined company’s name to “Ocugen, Inc.” Ocugen is expected to begin trading today on The Nasdaq Capital Market under the ticker symbol “OCGN.” The executive team of Ocugen has become the executive team of the
- Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa in the European Unionhttps://modernod.com/news/aerie-pharmaceuticals-receives-positive-chmp-opinion-for-rhokiinsa-in-the-european-union/2476906/Aerie Pharmaceuticals announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorization application (MAA) for Rhokiinsa (netarsudilophthalmic solution) 0.02%. The recommend
- Sifi Appoints New Country Manager for Italyhttps://modernod.com/news/sifi-appoints-new-country-manager-for-italy/2476904/Sifi has announced that Fabrizio Folco has joined the company as “Country Manager Italy,” and will be responsible for accelerating company development on the Italian market through management of the company’s commercial strategy and organization, for both pharma and surgical are
- Allergan and Molecular Partners Announce Acceptance of FDA BLA for Abicipar Pegol in Patients With Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-announce-acceptance-of-fda-biologics-license-application-for-abicipar-pegol-in-patients-with-wet-amd/2479537/Allergan and Molecular Partners announced that the FDA has accepted a biologics license application (BLA) and the European Medicines Agency (EMA) has validated a marketing authorization application (MAA) for Abicipar pegol, a novel, investigational DARPin therapy in patients with wet age-related
- Horus Pharma Launches Neovis Total Multi for Dry Eye in New Sizehttps://modernod.com/news/horus-pharma-launches-neovis-total-multi-for-dry-eye-in-new-size/2476843/Horus Pharma announced the launch of a new 15ml bottle of Neovis Total Multi for the French, Belgian, and Spanish markets. The product is prescribed as third-line therapy for the treatment of dry eyes with keratitis or dry keratoconjunctivitis, following unsuccessful treatment with low-viscosity
- Topcon Announces the Release of Harmony Into the EMEA Regionhttps://modernod.com/news/topcon-announces-the-release-of-harmony-into-the-emea-region/2476835/Topcon has announced the release and clearance of the Topcon Harmony, a class II medical diagnostic software, into the EMEA market. Topcon Harmony is a responsive browser-based software application for on-site or cloud-hosted environments that allows practitioners to connect all of their diagnost
- Now Optics Names Two Women to its Executive Leadership Teamhttps://modernod.com/news/now-optics-names-two-women-to-its-executive-leadership-team/2476834/Now Optics recently named two women to its leadership team. Former CVS Health’s Morgan Diaz joined Now Optics as senior vice president of operations and business development, and Lukana Justin previously from Office Depot Inc. is the new, senior vice president of marketing. They join Tara Pellegr
- AmblyoPlay Now Offers its Vision Therapy Solution for Lazy Eye in the United Stateshttps://modernod.com/news/amblyoplay-now-offers-its-vision-therapy-solution-for-lazy-eye-in-the-united-states/2476828/AmblyoPlay, a home-based vision therapy solution for children and adults with amblyopia (lazy eye), mild strabismus (crossed or turned eye) or convergence insufficiency (eyes unable to focus together), announced the launch of its software-based vision therapy solution in the U.S. market. I